Profile data is unavailable for this security.
About the company
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
- Revenue in USD (TTM)1.97bn
- Net income in USD92.93m
- Incorporated1996
- Employees5.90k
- LocationQiagen NVHulsterweg 82VENLO 5912 PLNetherlandsNLD
- Phone+31 773556600
- Fax+31 773208409
- Websitehttps://www.qiagen.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BB BIOTECH AG | 289.16m | 133.93m | 2.31bn | -- | 17.10 | 0.9544 | -- | 7.98 | 2.27 | 2.27 | 4.95 | 40.66 | 0.1077 | -- | -- | -- | 4.99 | 2.34 | 5.64 | 2.52 | 97.86 | 99.06 | 46.32 | 35.40 | -- | 2.17 | 0.1096 | 217.78 | -57.97 | -37.98 | 42.26 | -- | -- | -8.09 |
| BACHEM HOLDING AG | 617.26m | 121.33m | 5.97bn | 2.01k | 49.01 | 4.27 | 34.65 | 9.66 | 1.52 | 1.52 | 7.71 | 17.42 | 0.3585 | 1.06 | 4.33 | 288,020.40 | 7.05 | 8.85 | 8.10 | 10.28 | 31.04 | 31.63 | 19.66 | 19.74 | 1.57 | 100.82 | 0.0002 | 55.37 | 8.57 | 15.37 | 11.10 | 19.12 | 50.88 | 7.78 |
| Zealand Pharma A/S | 10.30m | -141.10m | 7.77bn | 298.00 | -- | 6.49 | -- | 753.94 | -16.69 | -16.69 | 1.21 | 125.74 | 0.013 | 3.73 | 0.2625 | 303,834.00 | -17.83 | -42.74 | -18.63 | -50.24 | 72.06 | 96.13 | -1,369.25 | -464.66 | 35.49 | -- | 0.042 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
| Qiagen NV | 1.86bn | 87.98m | 9.04bn | 5.90k | 104.68 | 2.69 | 31.58 | 4.85 | 0.3863 | 0.3863 | 8.33 | 15.04 | 0.3229 | 2.03 | 5.71 | 311,945.20 | 1.53 | 5.41 | 1.77 | 6.53 | 62.73 | 64.65 | 4.73 | 16.35 | 1.89 | -- | 0.3523 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
| Genmab A/S | 2.65bn | 621.89m | 13.76bn | 2.64k | 21.74 | 3.09 | 34.55 | 5.20 | 71.38 | 71.38 | 303.48 | 502.60 | 0.5277 | 10.98 | 3.37 | 8,966,878.00 | 12.39 | 17.43 | 13.76 | 18.59 | 96.08 | -- | 23.47 | 35.87 | 5.15 | -- | 0.03 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
| argenx SE | 1.76bn | -38.15m | 34.25bn | 1.15k | -- | -- | -- | 19.47 | -0.7951 | -0.7951 | 28.94 | -- | -- | -- | -- | 1,532,787.00 | -- | -17.65 | -- | -19.79 | 89.56 | -- | -2.17 | -97.72 | -- | -- | -- | -- | 198.56 | 117.25 | 58.42 | -- | 122.32 | -- |
| Lonza Group AG | 7.15bn | 612.16m | 43.06bn | 17.83k | 70.31 | 4.17 | 35.41 | 6.02 | 7.94 | 7.94 | 92.53 | 133.83 | 0.3767 | 2.60 | 4.35 | 372,000.00 | 3.23 | 5.07 | 3.81 | 6.21 | 29.21 | 39.15 | 8.57 | 14.52 | 1.38 | 5.14 | 0.2873 | 30.57 | 7.94 | 3.92 | -46.17 | -0.0306 | 23.95 | 7.78 |
